Biomimetic membrane materials designed to imitate biological transport systems represent powerful preliminary models for investigating molecular interactions at biologically relevant interfaces. In drug discovery, such systems enable the translation of molecular properties into functional behaviour at membrane surfaces, which is particularly important for central nervous system (CNS)-active compounds such as antidepressants. Their therapeutic outcomes critically depend on interactions with lipid bilayers and the ability to cross physiological barriers. Therefore, biomimetic membrane-based models can provide a structurally and functionally relevant basis for studying drug–surface interactions and transport phenomena. Biomimetic membrane interfaces were constructed using immobilized artificial membrane chromatography (IAM.PC DD2) representing phospholipid-like surfaces, and Permeapad systems simulating multilayer lipid barriers of the gastrointestinal tract, with complementary PAMPA permeability assessment. The study included sertraline, agomelatine and its structurally related analogues, enabling detailed evaluation of structure–retention relationships on IAM.PC and Permeapad surfaces. Retention behaviour on IAM.PC was interpreted in the context of biomimetic interactions, reflecting contributions of phospholipid headgroup binding, hydrogen bonding, and electrostatic effects, in contrast to purely hydrophobic partitioning observed on conventional phases. Transport across biomimetic interfaces was quantified through flux and absorption parameters under controlled physicochemical conditions. The obtained results demonstrate that the investigated compounds exhibit distinct interaction patterns at biomimetic membrane interfaces, governed by their structural and physico-chemical properties. Agomelatine and its analogues showed differentiated retention profiles on IAM.PC, highlighting the role of structural modifications in modulating membrane affinity through polar and hydrogen-bonding forces. Biomimetic relevance of the system was confirmed through its ability to predict biologically relevant properties, showing strong correlations with lipophilicity, pharmacokinetic descriptors, and permeability parameters (r > 0.90). Sertraline demonstrated strong affinity toward lipid-like surfaces, reflected in high transport rates across Permeapad membranes, consistent with its lipophilic character and low polarity. However, its reduced cumulative permeability suggests pronounced partitioning within membrane structures emphasizing interfacial retention phenomena. In contrast, more polar compounds displayed limited interaction with lipid surfaces and reduced permeability, unless modulated by environmental factors such as pH. Molecular-level analysis further supports that membrane-associated behaviour correlates with conformational adaptability and interaction stability at biomimetic interfaces. Biomimetic membrane materials and interfaces thus provide a structurally relevant and biologically informative models for studying drug–membrane interactions. By integrating IAM-based chromatographic surfaces, artificial lipid barriers, and complementary computational insights, it is possible to establish a direct link between molecular structure and functional behaviour at biological interfaces. This approach enables improved prediction of permeability and distribution of novel antidepressants and their analogues.